Tranexamic Acid vs Hydroquinone for Melasma: A Complete Comparison Guide

5 days ago
4 min read

Tranexamic acid (TXA) and hydroquinone (HQ) are the two most-discussed topical and oral agents for melasma: hydroquinone directly inhibits tyrosinase, the enzyme that produces pigment, while tranexamic acid works upstream by calming the vascular and inflammatory signals that keep melanocytes over-activated. Comparing tranexamic acid vs hydroquinone matters because melasma is a chronic, relapsing condition, and the two drugs differ sharply in potency, safety ceiling, and how long they can be used. Korean dermatology clinics, which treat some of the highest melasma volumes in the world, increasingly combine both rather than choosing one. This guide compares mechanisms, evidence, side effects, and how Korean protocols actually sequence them.

How Hydroquinone Works — and Why It Is Still the Reference Standard

Hydroquinone blocks tyrosinase and is cytotoxic to overactive melanocytes at higher concentrations, which is why 4% HQ, often compounded with a retinoid and a mild steroid as modified Kligman triple cream, remains the benchmark against which other melasma treatments are measured. Meta-analyses indexed on PubMed consistently show significant pigment reduction within 8 to 12 weeks. Its weaknesses are equally established: irritation and rebound are common, prolonged continuous use carries a risk of exogenous ochronosis (a paradoxical blue-grey darkening), and most guidelines therefore cap continuous use at roughly 3 to 4 months before a break. In Korea, HQ is prescription-based and typically dispensed as part of a supervised, time-limited course rather than an open-ended cream.

How Tranexamic Acid Works — the Upstream Approach

Tranexamic acid is an antifibrinolytic drug repurposed for pigmentation. In melasma it inhibits plasminogen-related signaling between keratinocytes, blood vessels, and melanocytes, reducing both the pigment stimulus and the vascular redness component that often coexists with melasma. It is used three ways: low-dose oral TXA (commonly 250 mg twice daily in published protocols), topical 2 to 5% formulations, and microneedling- or injection-assisted delivery in clinics. Randomized trials generally show oral TXA producing meaningful MASI score improvements within 8 to 12 weeks, particularly in refractory melasma. Because it does not bleach normal skin and does not cause ochronosis, it can be maintained longer, but oral use requires screening: patients with a history of thromboembolism, certain clotting risks, or specific hormonal contraceptive use are usually excluded.

Head-to-Head: Efficacy, Speed, and Durability

Direct comparisons suggest 4% hydroquinone clears pigment somewhat faster and more deeply in the epidermal component of melasma, while oral tranexamic acid performs comparably over 12 weeks in several trials and appears better at preventing early relapse while it is continued, likely because it addresses the vascular driver. Neither cures melasma; discontinuation of either is followed by gradual recurrence in a majority of patients if photoprotection lapses. Practical read: HQ is the sprinter, TXA is the pacer. For thick, long-standing dermal-mixed melasma, monotherapy with either tends to disappoint, which is why combination regimens now dominate specialist practice in Korea and elsewhere.

Side Effects and Safety Ceilings Compared

Hydroquinone's issues are local and cumulative: stinging, contact dermatitis, halo hypopigmentation of surrounding skin, and ochronosis risk with prolonged unsupervised use, which is why several markets restrict over-the-counter sales. Tranexamic acid's issues are systemic and screening-dependent: gastrointestinal upset and headache are the common ones, while the theoretical thromboembolic risk at melasma doses appears low in published cohorts of screened patients but makes medical screening non-negotiable. Topical TXA is the gentlest of all options with the mildest evidence base. Pregnant patients are generally advised to defer both drugs. None of this replaces individual medical advice; both agents should run under clinician supervision.

How Korean Clinics Sequence TXA and HQ in Practice

A common Korean protocol for a moderate mixed melasma case looks like this: strict photoprotection from day one, oral tranexamic acid for 2 to 3 months as the systemic backbone, a supervised hydroquinone or triple-cream course targeting the darkest patches for 8 to 12 weeks, then transition to non-HQ maintenance (azelaic acid, cysteamine, or topical TXA) while continuing sun discipline. Low-fluence laser toning or pico laser sessions are often layered in cautiously, since aggressive laser settings can worsen melasma. The strategic logic is complementary mechanisms: TXA suppresses the stimulus, HQ clears the existing pigment, maintenance agents hold the result. Clinics also verify Fitzpatrick skin type before any energy-based add-on.

Cost and Access for International Patients in Korea

Both drugs are inexpensive relative to procedures. A dermatology consultation in Seoul commonly runs approximately 30,000 to 100,000 KRW at international-patient clinics; a month of oral TXA is typically in the tens of thousands of KRW, and prescription HQ compounds are similarly modest. The larger spend is usually the accompanying laser-toning packages, often quoted at approximately 100,000 to 300,000 KRW per session. A realistic melasma budget is therefore driven by how many clinic sessions you add, not by the medication itself. Figures are indicative 2026 market ranges and vary by clinic; confirm in writing.

Frequently Asked Questions

Which is better for a first-time melasma patient?

Most specialists start with photoprotection plus either a supervised HQ course or oral TXA depending on your melasma pattern, medical history, and thrombosis risk screening. Vascular-rich, recurrent melasma often favors adding TXA early; a first localized epidermal patch often responds to HQ alone.

Can tranexamic acid and hydroquinone be used together?

Yes, and combination use is common in Korean protocols because the mechanisms are complementary. Trials of combined regimens generally report better MASI improvement than monotherapy, with no unexpected interaction, under medical supervision.

How long until I see results from either drug?

Both typically show visible improvement in the 8 to 12 week window. Judging either drug before 8 weeks usually leads to premature switching. Maintenance planning matters more than speed, because melasma relapses without it.

Is oral tranexamic acid safe to buy without a prescription?

No. Oral TXA requires screening for clotting risk factors and is prescription-only in Korea and most countries. Self-sourcing it online skips the exact safety step that makes the published risk profile look acceptable.

Sources

Clinical references used for this guide: PubMed: tranexamic acid melasma trials · PubMed: hydroquinone melasma meta-analyses · KHIDI (Korea Health Industry Development Institute)

This article is general information and does not replace an individual dermatology consultation. Melasma treatment must be matched to your skin type, pattern, and medical history, and both drugs discussed here are supervision-dependent. If you are planning a skin-focused visit to Korea, book a consultation that includes Wood's lamp or spectrometry assessment before committing to any package.